Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference
Corsair Pharma, Inc., a private biopharmaceutical company, today announced three presentations related to its clinical program at the Pulmonary Hypertension Association (PHA) meeting taking place June 11-14, 2026, in Dallas, Texas. Corsair is developing the TRX-248 Transdermal System, an investigational once-daily transdermal patch for the treatment of pulmonary arterial hypertension (PAH). Positive Phase 1 pharmacokinetic, tolerability, and dosing data from healthy volunteers were recently announced, and these presentations will provide additional details on the study results.
Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension
Corsair Pharma, Inc., a private biopharmaceutical company, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating the TRX-248 Transdermal System, a once-daily transdermal patch designed for the treatment of pulmonary arterial hypertension (PAH).
Corsair Pharma to Present New Data on Proprietary Treprostinil Prodrug Transdermal System at PHPN 2025 Symposium
Corsair Pharma, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative transdermal therapies for pulmonary arterial hypertension (PAH), today announced it will present new data on the TRX-248 Transdermal System at the upcoming Pulmonary Hypertension Professional Network (PHPN) Symposium, taking place September 18–20, 2025, in Seattle, Washington.
Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System
Corsair Pharma, Inc., a private biopharmaceutical company, today announced the successful completion of the preclinical program of its TRX-248 Transdermal System, a once-daily transdermal patch for the treatment of Pulmonary Arterial Hypertension (PAH). These positive results support the initiation of a Phase 1 human trial expected to begin in the second quarter of 2025.
Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer
Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the appointment of George W. Mahaffey as Chief Executive Officer. He will also serve as a Director of the Company. Mr. Mahaffey brings more than 35 years of pharmaceutical, biotech, device, and diagnostics experience, including having launched Ventavis®, the first FDA-approved inhaled prostacyclin product indicated for pulmonary arterial hypertension (PAH).
